Throughout 2025, the team at SMA News Today has brought our audience the latest advances in spinal muscular atrophy (SMA), from emerging treatments and clinical trial updates to real-world research. As the year comes to a close, we’ve taken a look back at the top 10 stories that…
A medicine called leuprorelin acetate, approved in the U.S. to treat prostate cancer, can slow the progression of physical disability in people with spinal and bulbar muscular atrophy (SBMA), according to an analysis of a real-world study from Japan. Given certain limitations in the study’s design, the researchers stressed that…
Discussion
The other day, I got my wheelchair stuck in a doorway. All I wanted to do was see the Christmas decorations at a local coffee shop. Perhaps even enjoy a nice cup of their matcha while quietly watching everything sparkle. Instead, I was wedged in the doorway, pushing my joystick…
Discussion
Thanksgiving and Christmas are holidays that make me grateful. I am thankful for the birth of my Lord and Savior, Jesus, and how he not only brought me through all the events of this year in one piece, but also made me triumphant in many areas. One of my favorite…
Discussion
The magic of theater is that it’s live. Despite having a script, cues, rehearsals, and anything else the cast and crew can use to achieve consistency, the live nature of theater means the production remains mutable. You can’t “lock in” scenes like you can with film. Plus, not only will…
Last month’s approval of Novartis‘ one-time gene therapy Itvisma (onasemnogene abeparvovec-brve) for people with spinal muscular atrophy (SMA) ages 2 and older is a milestone that “ushers in a new era of informed therapeutic choice,” according to Angela Lek, PhD, chief research officer at the Muscular…
Get regular updates to your inbox.
